
    
      This is a Phase 3, multicenter, open-label, randomized, controlled study to determine the
      efficacy and safety of lenalidomide as maintenance therapy versus observation in patients
      with MCL in complete or partial remission after first line intensified and high-dose
      chemotherapy additioned with rituximab and followed by ASCT. This study will be conducted in
      three phases: a Screening Phase, a Treatment Phase and a Follow-up Phase
    
  